| Species |
Human |
| Protein Construction |
| hFc |
TNFRSF12A/TWEAKR (Glu28-Per80)
Accession # Q9NP84-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TNFRSF12A/TWEAKR hFc Chimera, Human at 1μg/ml (100μl/Well) on the plate can bind Biotinylated AntiTNFRSF12A Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
32.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Thyroid cancer (TC) is the most well-known endocrine neoplasia as well as a common malignant tumor in the head and neck.TNFRSF12A expression may be a potential useful prognostic molecular biomarker of bad survival in thyroid cancer, in addition, PPAR signaling pathway, insulin signaling pathway, mTOR signaling pathway may be the key pathway controlled by TNFRSF12A in thyroid cancer. Further experimental ought to be performed to demonstrate the biologic effect of TNFRSF12A. |
| Synonyms |
FGF-inducible 14; Fgfrp2; TNFRSF12A; FN14; CD266; TWEAKR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
